» Articles » PMID: 20190029

Impact of C-reactive Protein and Pulse Pressure Evaluated at the Start of Peritoneal Dialysis on Cardiovascular Events in the Course of Treatment with Peritoneal Dialysis

Overview
Journal Perit Dial Int
Publisher Sage Publications
Date 2010 Mar 2
PMID 20190029
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite a reduced number of infectious complications, cardiovascular (CV) mortality remains unchanged in peritoneal dialysis (PD) patients. The aim of this study was to evaluate the effects of high-sensitivity C-reactive protein (hs-CRP) and pulse pressure (PP) at the start of PD on the development of CV events (CVEs) in these patients.

Methods: The study population was comprised of 291 patients that started PD between January 2003 and June 2008 and were treated for more than 6 months. Baseline clinical, biochemical, and echocardiographic data, indices of dialysis adequacy, and peritoneal transport rate were reviewed retrospectively. The clinical outcome was the occurrence of a CVE.

Results: Mean duration of follow-up was 28 (range 6 - 70) months. A CVE was observed in 33 patients (11.3%). The 1-, 3-, and 5-year cumulative incidences of CVEs were 4.0%, 13.7%, and 27.5%, respectively. Although multiple variables were correlated with the prevalence of a CVE in the univariate analysis, hs-CRP, PP, and comorbidity remained significant after adjustment: hs-CRP: odds ratio (OR) 4.09 (1.53 - 10.95), p = 0.005; PP: OR 2.79 (1.26 - 6.17), p = 0.012. PP and hs-CRP, which were not intercorrelated in our data, combined adversely to increase the incidence of CVEs. The incidence of CVEs increased with the number of risk factors, which included high hs-CRP, high PP, and the presence of comorbidity (no risk factor, 0%; 1 risk factor, 1.5%; 2 risk factors, 30.8%; 3 risk factors, 53.9%).

Conclusions: Our study suggests that measurements of hs-CRP and PP at the start of PD may be helpful in predicting the development of CVEs in the course of treatment with PD.

Citing Articles

Serum Malondialdehyde-Modified Low-Density Lipoprotein Level May Be a Biomarker Associated with Aortic Stiffness Among Patients Undergoing Peritoneal Dialysis.

Chang Y, Wang C, Tang C, Lin Y, Lai Y, Kuo C Life (Basel). 2024; 14(11).

PMID: 39598185 PMC: 11595923. DOI: 10.3390/life14111385.


Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.

Mikolasevic I, Milic S, Racki S, Zaputovic L, Stimac D, Radic M Perit Dial Int. 2015; 36(4):427-32.

PMID: 26475841 PMC: 4934438. DOI: 10.3747/pdi.2014.00223.


ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors.

Wang A, Brimble K, Brunier G, Holt S, Jha V, Johnson D Perit Dial Int. 2015; 35(4):379-87.

PMID: 26228782 PMC: 4520720. DOI: 10.3747/pdi.2014.00279.


Predictive value of echocardiographic parameters for clinical events in patients starting hemodialysis.

Han S, Cho G, Park Y, Baek S, Ahn S, Kim S J Korean Med Sci. 2015; 30(1):44-53.

PMID: 25552882 PMC: 4278026. DOI: 10.3346/jkms.2015.30.1.44.


The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis.

Koo H, Kim C, Doh F, Lee M, Kim E, Han J PLoS One. 2014; 9(2):e87231.

PMID: 24505281 PMC: 3914817. DOI: 10.1371/journal.pone.0087231.